Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
bioportfolio.co.uk SUZHOU, China, June 2, 2020 /PRNewswire/BioPortfolio.co.uk/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today...
http://dlvr.it/RXsXBw
http://dlvr.it/RXsXBw
Comments
Post a Comment